Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- C.H. Robinson acquires DeSpir Logistics for $75 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
